gdc
FDA Approvals, News & UpdatesOvarian Cancer

Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations.
June 2020 Vol 6 No 3

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy. Zejula was previously approved for several types of ovarian cancer, including patients with HRD-positive disease, defined by the presence of the BRCA gene mutation or genomic instability.

Since late 2018, women with ovarian cancer and a BRCA mutation whose cancer responded to initial treatment with chemotherapy were eligible to receive treatment with a PARP inhibitor, including Zejula or Lynparza (olaparib).

This approval was based on the results of a clinical trial of 733 patients with ovarian cancer who had a response to first-line platinum-based chemotherapy. Patients received first-line maintenance treatment with Zejula or with placebo.

The results showed significantly longer time without cancer progression in patients who received Zejula compared with patients who received placebo, regardless of HRD status. The average time without cancer progression in patients with HRD-positive status was 21.9 months with Zejula versus 10.4 months with placebo. The average time without cancer progression in all the patients was 13.8 months with Zejula versus 8.2 months with placebo.

The most common side effects with Zejula in the PRIMA study were thrombocytopenia (reduced platelets), anemia, nausea, fatigue, neutropenia, constipation, muscle pain, headache, insomnia, vomiting, dyspnea, decreased appetite, dizziness, cough, hypertension, and kidney injury.

Recommended For You
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesLeukemia
First-Line Treatment with Calquence Produces Long-Term Responses in Patients with Chronic Lymphocytic Leukemia
By Dana Taylor
The FDA approved a new Bruton tyrosine kinase (or BTK), Calquence, for first-line treatment of patients with CLL.
CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Last modified: July 7, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country